References
- Steinberg GD. Cancer Bulletin 1986: Feb: 1–18
- National Institutes of Health Consensus Development Conference. The management of clinically localized prostate cancer. J Urol 1988: 138: 1369–75
- Donohue RE, Mani JH, Whitesel JA, et al. Pelvic lymph node dissection: guide to patient management and clinically locally confined adenocarcinoma of prostate. Urology 1982: 20(6): 559–65
- Barzell W, Bean MA, Hilaris BS, et al. Prostatic adenocarcinoma: relationship of grade and local extent to the pattern of metastases. J Urol 1977: 118(2): 278–82
- Walsh PC, Donker PJ. Impotence following radical prostatectomy: insight into etiology and prevention. J Urol 1982: 128(3): 492–7
- Freiha FS, Bagshaw MA. Carcinoma of the prostate: results of post-irradiation biopsy. Prostate 1984: 5(1): 19–25
- Cantrell BB, DeKlerk DP, Eggleston JC, et al. Pathological factors that influence prognosis in stage A prostatic cancer: the influence of extent versus grade. J Urol 1981: 125(4): 516–20
- McMillen SM, Wettlaufer JN. The role of repeat transurethral biopsy in stage A carcinoma of the prostate. J Urol 1976: 116(6): 759–60
- Bridges CH, Belville WD, Insalaco SJ, et al. Stage A prostatic carcinoma and repeat transurethral resection: a reappraisal 5 years later. J Urol 1983: 129(2): 307–8
- Smith JA Jr, Middleton RG. Stage A carcinoma of the prostate in clinical management of prostatic cancer. Chicago: Year Book Medical Publishers. 1987: 85–96
- Catalona WJ, Stein AJ. Staging errors in clinically localized prostatic cancer. J Urol 1982: 127(3): 452–6
- Catalona WJ. Radical prostatectomy. In: Catalona WJ, ed. Prostate cancer. New York: Grune & Stratton, 1984: 85–116
- Chopp RT, Whitmore WF. Delayed treatment of prostatic carcinoma. American Urologlcal Association Abstract No. 234, 1980
- Walsh PC, Jewett HJ. Radical surgery for prostatic cancer. Cancer 1980: 45 (Suppl 7): 1906–11
- Paulson DF, Lin GH, Hinshaw W, et al. Radical surgery versus radiotherapy for adenocarcinoma of the prostate. J Urol 1982: 128(3): 502–4
- Paulson DF. Radiotherapy versus surgery for localized prostatic cancer. Urol Clin North Am 1987: 14(4): 675–84
- Soloway MS. Newer methods of hormonal therapy for prostate cancer. Urology 1984: 24(Suppl 5): 30–8
- Hickey D, Todd B, Soloway MS. Pre-treatment testosterone levels: significance in androgen deprivation therapy. J Urol 1986: 136(5): 1038–40
- Harper ME, Pierrepoint CG, Griffiths K. Carcinoma of the prostate: relationship of pretreatment hormone levels to survival. Eur J Cancer Clin Oncol 1984: 20(4): 477–82
- Glashan RW, Robinson MR. Cardiovascular complications in the treatment of prostatic carcinoma. Br J Urol 1981: 53(6): 624–7
- Henriksson P, Edhag O. Orchidectomy versus oestrogen for prostatic cancer: cardiovascular effects. Br Med J 1986: 293: 413–5
- Schally AV, Arimura A, Baba T, et al. Isolation and properties of the FSH and LH-releasing hormone. Biochem Biophys Res Commun 1971: 43(2): 393–9
- The Leuprolide Study Group. Leuprolide versus diethylstiibestrol for metastatic prostatic cancer. N Engl J Med 1984: 311(20): 1281–6
- Sogani PC, Vagaiwala MR, Whitmore WF Jr. Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy. Cancer 1984: 54(4): 744–50
- Crawford ED, McLeod LD, Dorr A, et al. A comparison of leuprolide with flutamide and leuprolide in previously untreated patients with clinical stage D2 cancer of the prostate: a phase III intergroup study. J Urol 1987: 137: 610
- Eisenberger MA, Bezerdjian L, Kalash S. Critical assessment in the role of chemotherapyin endocrine-resistant prostatic carcinoma. Urol Clin North Am 1987: 14(4): 695–706
- Hickey D, Cant J, Soloway MS. Failure of chemotherapy to prolong life in patients with metastatic prostate cancer who have failed androgen deprivation. Urology 1988: 31(1): 38–40